August 2019
No Images? Click here
The latest technology to license from Oxford
Virtual Assay drug screening
A drug discovery method to identify new chemical entities and test for safety and efficacy could one day be conducted by a computer rather than on animals.
A catalyst for sustainable fuels
A novel and sustainably formed catalytic system for the hydrogenation of carbon dioxide and or carbon monoxide to form the desired jet fuels.
Biologically inspired lighting
A new method to generate metamers with non-linear light sources using an algorithm which incorporates spectral shifts in real light sources.
Wireless power line detection
A dedicated device to scan and detect electromagnetic signals emitted from power lines that indicate the presence of power line data networks.
Sickle cell screening during pregnancy
A high-throughput, non-invasive prenatal testing technique for the diagnosis of sickle-cell disease in the foetus.
A fresh look at chemical recycling
A novel and more effective way to convert waste plastic back into its constituent monomers with very high selectivity.
Predicting the growth of aortic aneurysms
A method to predict the growth rate of abdominal aortic aneurysms in humans using the pulsation characteristics of an artery during ultrasound imaging.
The Challenges of deep vein thrombosis
A quick and accurate point-of-care solution that can improve screening of DVT patients in primary care, avoiding the need for unnecessary referrals and treatments.
Targeted drug delivery for brain diseases
Drug delivery nano-system capable of directly targeting areas of the brain affected by abnormal tau aggregation, in diseases such as Alzheimer’s disease.
The next generation display technology
A phase change material switching device, which can be used in the next generation of reflective displays.
Improved data analysis and design tool
A flexible method for simplifying the analysis of datasets arising from highly complex high throughput screening experiments.
Targeting complex diseases with simple medicines
Using a combination of chemistry and synthetic biology, spinout company GyreOx utilises proprietary engineered enzymes to create novel medicines that address complex intracellular drug targets.
For more details, please contact Richard Reschen
Oxford University Innovation (OUI) has sent this newsletter to you because either you have subscribed to receive it
or we believe it will be of interest to you. OUI's Privacy Policy is here.
You may unsubscribe at anytime (see below), or amend your subscription on our website.
Oxford University Innovation Ltd, the technology commercialisation company of the University of Oxford.
Buxton Court, 3 West Way, Oxford, OX2 0JB | +44 (0)1865 280830 |